Acurx Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACXP research report →
Price Chart
About the company
Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme.
- CEO
- David Luci
- IPO
- 2021
- Employees
- 4
- HQ
- Staten Island, NY, US
Get TickerSpark's AI analysis on ACXP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $6.30M
- P/E
- -0.37
- Fwd P/E
- 1.37
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.75
- EV/EBITDA
- 0.41
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -116.60%
- ROIC
- -112.64%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-8,091,983
- Net Income
- $-7,966,538+43.5%
- EPS
- $-5.32+69.8%
- OCF Growth
- +34.6%
- FCF Growth
- +34.6%
- 52W High
- $7.54
- 52W Low
- $0.90
- 50D MA
- $1.17
- 200D MA
- $1.86
- Beta
- -2.08
- RSI (14)
- 46
- Avg Volume
- 97.29K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
AcuRx said it advanced its recurrent C. diff program, started PATHFINDER enrollment, and ended the quarter with $9.7 million in cash while posting a $2.6 million net loss.· November 12, 2026
- PATHFINDER enrollment began on September 29 for a 20-patient recurrent C. diff study that management says could help support an NDA path.
- The company said FDA was open to further discussion after ASPIRE and PATHFINDER data are available, with the key question being whether the efficacy package is robust enough for submission.
- Management outlined two possible paths: proceed with ASPIRE if funded, or potentially move to a shorter, smaller PATHFINDER 2 program under the LPAD pathway if ASPIRE is not funded.
- Cash was $9.7 million at quarter-end, up from $7.6 million at December 31, 2025, after about $1.5 million of gross proceeds from the equity line of credit.
- R&D spending rose on PATHFINDER-related costs, while G&A fell year over year for both the quarter and first nine months.
For the third quarter ended September 30, 2026, Acurx reported cash of $9.7 million versus $7.6 million at December 31, 2025. It raised approximately $1.5 million of gross proceeds through its equity line of credit during the quarter. R&D expense was $1.1 million versus $400,000 in the prior-year quarter, driven mainly by $700,000 of higher consulting costs tied to the new recurrent CDI trial program. G&A expense was $1.5 million versus $1.6 million a year earlier. The company reported a net loss of $2.6 million, or $0.49 per diluted share, versus a net loss of $2.0 million, or $1.23 per diluted share, in the prior-year quarter. For the first nine months of 2026, R&D was $2.5 million versus $1.6 million, G&A was $4.1 million versus $4.9 million, and net loss was $6.5 million, or $1.59 per diluted share. Management said it has enough funds to pay for the recurrent CDI trial assuming full enrollment in the third quarter of 2027, with 12 months of funds secured; it also said it may raise additional cash through ELOC drawdowns, equity offerings, partnerships, or government grants.
David Luci focused on regulatory progress, trial execution, and the company’s strategic flexibility. He said the FDA was open to discussing the totality of evidence from ibezopolstat after ASPIRE and PATHFINDER are complete, and that the recently started PATHFINDER trial could support a potentially smaller development program if results are strong. He also highlighted brand, patent, and partnership milestones, describing the company as well positioned to advance toward commercialization and as confident despite industry challenges.
Robert G. Shawah emphasized liquidity and expense trends. He said cash totaled $9.7 million at September 30, 2026, compared with $7.6 million at year-end 2025, and noted about $1.5 million of gross proceeds from the equity line of credit. He detailed that Q3 R&D was $1.1 million, up from $400,000, mainly due to PATHFINDER-related consulting costs, while G&A was $1.5 million versus $1.6 million. For the first nine months, R&D was $2.5 million and G&A was $4.1 million, and he reported a net loss of $6.5 million for the period.
Analysts focused on whether PATHFINDER 2 could be prioritized over ASPIRE, what would drive that decision, and what FDA might require to advance a smaller program. Management said the company may need to “call an audible” depending on funding and data: if ASPIRE is funded, it would start right away; if not, positive recurrent CDI data could support a shorter, less costly PATHFINDER 2 path. On PATHFINDER 2, management suggested a study of about 350 patients over 1.5 to 2 years, likely international, and said FDA would be looking for long-term recurrence data that could show non-inferiority or superiority versus approved recurrent C. diff therapies. Management also addressed cash, saying it has enough funds to continue the rCDI trial with 12 months of funds secured and potential additional funding sources available.
The bull case on this call is that Acurx believes it has a credible regulatory and clinical path for ibezopolstat, backed by ongoing FDA dialogue and newly started PATHFINDER enrollment. Management was upbeat about the drug’s differentiating profile, including microbiome-sparing attributes and data suggesting strong activity against C. difficile and recurrence. They also pointed to patents, QIDP/Fast Track status, and potential partnership interest as additional supports for value creation.
The main risks are funding and execution: the company is still dependent on raising capital, and management openly said future funding may come from equity, grants, or partnerships. The regulatory path is not settled, since ASPIRE is not yet funded and the company may need to choose between multiple development options based on future data and FDA feedback. Enrollment timing remains uncertain, with top-line recurrent CDI data expected only after enrollment completes sometime in the second half of 2027.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 91.9%
- Shares Outstanding
- 6.06M
- Float Shares
- 5.57M
of shares held by institutions
19 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Capital Management LLC | 31.10K | 0 |
| Geode Capital Management, LLC | 26.30K | ▼ 114 |
| Xtx Topco Ltd | 24.12K | ▲ 24.12K |
| Vanguard Group Inc | 23.28K | ▲ 23.28K |
| Vanguard Fiduciary Trust Co | 16.20K | 0 |
| Lanark Financial, Inc. | 15.20K | ▲ 13.70K |
| Cambridge Investment Research Advisors, Inc. | 15.00K | ▲ 15.00K |
| Prospect Financial Services LLC | 13.29K | ▼ 500 |
| Jane Street Group, LLC | 12.96K | ▼ 2.77K |
| Hrt Financial LP | 10.01K | ▲ 10.01K |
| Morgan Stanley | 7.50K | 0 |
| Integrated Wealth Concepts LLC | 4.73K | ▲ 4.73K |
Held by 6 ETFs
Biggest fund positions in ACXP by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 20, 26 | Sailer Carl | other | 2,150 |
| Apr 20, 26 | DEAN JACK H | other | 2,150 |
| Apr 20, 26 | Donohue James J. | other | 2,150 |
| Apr 20, 26 | HARRISON THOMAS L | other | 2,150 |
| Apr 20, 26 | Scodari Joseph C | other | 2,150 |
| Apr 20, 26 | DELUCCIA ROBERT J | other | 37,100 |
| Apr 20, 26 | LUCI DAVID P | other | 37,100 |
| Apr 20, 26 | Shawah Robert G. | other | 25,900 |
| Feb 5, 25 | Shawah Robert G. | other | 145,500 |
| Feb 5, 25 | LUCI DAVID P | other | 250,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ACXP coverage
Recent articles, reports, and earnings notes.
No research on ACXP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ACXP report →Acurx Pharmaceuticals, Inc. (ACXP) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 12
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2026 results and provides business update
prnewswire.com · Nov 12
Acurx Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 12, 2026 Conference Call and Provide Business Update
prnewswire.com · Oct 26
Acurx Announces Publication in ASM Confirming Data on its DNA pol IIIC Inhibitor Pipeline of Antibiotics Demonstrating a Potential Microbiome-Sparing Class Effect
prnewswire.com · Oct 21
Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection
prnewswire.com · Sep 29
Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs.
prnewswire.com · Sep 14
Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat
prnewswire.com · Aug 17
Acurx Pharmaceuticals, Inc. (ACXP) Q2 2026 Earnings Call Transcript
seekingalpha.com · Aug 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.